About COMPASS Pathways
COMPASS Pathways is a company based in London (United Kingdom) founded in 2016 by Lars Christian Wilde. COMPASS Pathways has raised $108.55 million across 3 funding rounds from investors including RA Capital, Perceptive Advisors and Aisling Capital. The company has 166 employees as of December 31, 2024. COMPASS Pathways offers products and services including COMP360 Psilocybin and Therapist Training. COMPASS Pathways operates in a competitive market with competitors including ATAI, Beckley Psytech, MindMed, Cybin and Delix Therapeutics, among others.
- Headquarter London, United Kingdom
- Employees 166 as on 31 Dec, 2024
- Founders Lars Christian Wilde
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Compass Pathways Plc Sponsored Adr
-
Annual Revenue
Not available
-
Net Profit
-$155.19 M (USD)-30.49as on Dec 31, 2024
-
EBITDA
-$178.05 M (USD)-29.77as on Dec 31, 2024
-
Total Equity Funding
$108.55 M (USD)
in 3 rounds
-
Latest Funding Round
$285 M (USD), Post-IPO
Aug 16, 2023
-
Investors
RA Capital
& 16 more
-
Employee Count
166
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of COMPASS Pathways
COMPASS Pathways is a publicly listed company on the NASDAQ with ticker symbol CMPS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of COMPASS Pathways
COMPASS Pathways offers a comprehensive portfolio of products and services, including COMP360 Psilocybin and Therapist Training.
Investigational therapy for mental health disorders like depression
Program for training professionals in psilocybin therapy methods
People of COMPASS Pathways
Unlock access to complete
Unlock access to complete
Funding Insights of COMPASS Pathways
COMPASS Pathways has successfully raised a total of $108.55M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $285 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in COMPASS Pathways
COMPASS Pathways has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, Perceptive Advisors and Aisling Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Venture capital and private equity firm
|
Locked | Locked | Locked | |
|
Investment in transformative therapeutics is managed by the firm.
|
Locked | Locked | Locked |
Investor details for COMPASS Pathways
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by COMPASS Pathways
Investment portfolio details for COMPASS Pathways
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - COMPASS Pathways
Detailed financials for COMPASS Pathways
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Compass Pathways Comparisons
Peer comparison for COMPASS Pathways
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of COMPASS Pathways
COMPASS Pathways operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ATAI, Beckley Psytech, MindMed, Cybin and Delix Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of neurological and psychiatric disorders
|
|
| Locked | Locked | Locked |
Psychedelic-based therapies for brain health disorders are developed.
|
|
| Locked | Locked | Locked |
Psychedelic therapeutics for psychiatric disorders are developed and provided.
|
|
| Locked | Locked | Locked |
Non-hallucinogenic therapeutics for neurological disorders are developed.
|
Detailed competitors of COMPASS Pathways
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Compass Pathways
Complete news archive for COMPASS Pathways
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about COMPASS Pathways
COMPASS Pathways was founded in 2016 and raised its 1st funding round 2 years after it was founded.
COMPASS Pathways is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Kabir Nath is the current CEO of COMPASS Pathways.
COMPASS Pathways is a funded company, having raised a total of $108.55M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at COMPASS Pathways is 166.
COMPASS Pathways was founded in 2016 in London, United Kingdom. Focus is placed on the biotechnology sector, where therapies for mental disorders are developed. Psilocybin-based treatments for treatment-resistant depression are advanced, with psilocybin functioning as a partial agonist at multiple serotonin receptors. Operations center on clinical research and therapeutic innovation in mental health.
COMPASS Pathways's top competitors include MindMed, Beckley Psytech and Psylo.
COMPASS Pathways offers COMP360 Psilocybin and Therapist Training.
Yes, COMPASS Pathways is publicly traded on NASDAQ under the ticker symbol CMPS.
COMPASS Pathways has 17 investors. Key investors include RA Capital, Perceptive Advisors, Aisling Capital, Vivo Capital, and Surveyor Capital.
The ticker symbol of COMPASS Pathways is CMPS on NASDAQ.